



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2025-2026

LFIR # 1102

1. Project Title

2. Senate Sponsor

3. Date of Request

4. Project/Program Description

Enable robust SUS-Insightec collaboration for next-gen HIFU/LIFU R&D &/or clinical trials in AD, brain CA, addiction, autism, PTSD, PD, & Neuro Degenerative conditions. Partnership accelerates R&D for brain drug/gene delivery, neuromod, ablation, diagnostics. Focus includes proof-of-concept, pilot data, & multicenter trials. BOG->company funding fosters synergy. IP remains with manufacturer, ensuring rapid innovation. Goal: advanced therapy, streamlined translation, global impact.

5. State Agency to receive requested funds

State Agency contacted? Yes

6. Amount of the Nonrecurring Request for Fiscal Year 2025-2026

Type of Funding	Amount
Operating	5,000,000
Fixed Capital Outlay	0
Total State Funds Requested	5,000,000

7. Total Project Cost for Fiscal Year 2025-2026 (including matching funds available for this project)

Type of Funding	Amount	Percentage
Total State Funds Requested (from question #6)	5,000,000	100%
Matching Funds		
Federal	0	0%
State (excluding the amount of this request)	0	0%
Local	0	0%
Other	0	0%
Total Project Costs for Fiscal Year 2025-2026	5,000,000	100%

8. Has this project previously received state funding? Yes

If yes, provide the most recent instance:

Fiscal Year (yyyy-yy)	Amount		Specific Appropriation #	Vetoed
	Recurring	Nonrecurring		
2024-25	0	5,000,000	147	No

9. Is future-year funding likely to be requested? Yes

a. If yes, indicate nonrecurring amount per year.

b. Describe the source of funding that can be used in lieu of state funding.

University operating funds; private funds



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2025-2026

LFIR # 1102

Complete questions 10 and 11 for Fixed Capital Outlay Projects

10. Status of Construction

a. What is the current phase of the project?

- Planning
 Design
 Construction
 N/A

b. Is the project "shovel ready" (i.e permitted)?

c. What is the estimated start date of construction?

d. What is the estimated completion date of construction?

e. What funding stream will be used for ongoing operations and maintenance of the project?

11. List the owners of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owners of the facility and the entity.

12. Details on how the requested state funds will be expended

Spending Category	Description	Amount
Administrative Costs:		
Executive Director/Project Head Salary and Benefits		0
Other Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other	Other, also include equipment/expenses/travel/supplies/consultants/contract services/study. Funds cover direct R&D/trial costs to refine Exablate Neuro HIFU/LIFU, enabling new updates delivered to existing systems. Enhancements expand noninvasive diagnostic/treatment capabilities for in-state, interstate, international institutions, to advance patient care & driving ongoing tech innovation.	5,000,000
Consultants/Contracted Services/Study		0
Operational Costs		
Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other		0
Consultants/Contracted Services/Study		0
Fixed Capital Construction/Major Renovation:		
Construction/Renovation/Land/Planning Engineering		0
Total State Funds Requested (must equal total from question #6)		5,000,000

13. Program Performance

a. What specific purpose or goal will be achieved by the funds requested?



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2025-2026

LFIR # 1102

Enable robust SUS-Insightec collaboration for next-gen HIFU/LIFU R&D &/or clinical trials in AD, brain CA, addiction, autism, PTSD, PD, & Neuro Degenerative conditions. Partnership accelerates R&D for brain drug/gene delivery, neuromod, ablation, diagnostics. Focus includes proof-of-concept, pilot data, & multicenter trials. BOG->company funding fosters synergy. IP remains with manufacturer, ensuring rapid innovation. Goal: advanced therapy, streamlined translation, global impact.

b. What activities and services will be provided to meet the intended purpose of these funds?

Enhanced Exablate technology, developed under BOG-Insightec contract for R&D, may eventually be implemented at partner health systems to diagnose and/or treat AD, brain CA, addiction, and other disorders, driving next-gen solutions in collaboration with national/international centers & delivering direct patient services in clinical trials.

c. What direct services will be provided to citizens by the appropriation project?

Advanced Exablate solutions may provide noninvasive diagnostics and treatments for AD, brain CA, addiction, PD, PTSD, and other brain conditions. By facilitating R&D and/or clinical trials and rapid deployment of innovations, the program aims to gain FDA approvals in accelerated timelines and deliver access to cutting-edge therapies and improved outcomes and quality of life.

d. Who is the target population served by this project? How many individuals are expected to be served?

Elderly persons, persons with poor mental health, economically disadvantaged persons, persons with brain diseases (Alzheimer's, autism, neuro-degenerative)

e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?

Collaborative R&D may broaden noninvasive treatment possibilities, potentially enhancing symptom management and care options for various brain disorders. This partnership, over time, could potentially lead to improved diagnostics and broader innovations that support future healthcare advancements. Outcome measurement will derive from R&D milestones, published insights, and technology enhancements generated through the Insightec-BOG collaboration. Metrics may include peer-reviewed findings, pilot study data, and adoption rates among participating institutions, creating a flexible, high-level framework for gauging overall benefit.

f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for in the contract?

Return of state funds.

14. Is this project related to mitigation, response, or recovery from a natural disaster?

a. If Yes, what phase best describes the project?

- Mitigation (reducing or eliminating potential loss of life or property)
- Response (addressing the immediate and short-term effects of a natural disaster)
- Recovery (assisting communities return to normal operations, including rebuilding damaged infrastructure)

b. Name of the natural disaster (or Executive Order # for events not under a federal declaration):

15. Has the entity applied for or received federal assistance for this project?

- Yes, Applied
- Yes, Received
- No



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2025-2026

LFIR # 1102

No, but intends to apply

a. If yes, provide the FEMA project worksheet ID#:

b. Provide the total project cost listed on the FEMA project worksheet:

16. Has the entity applied for or received state assistance for this project (other than this request)?

Yes, Applied

Yes, Received

No

No, but intends to apply

a. If yes, specify the program and state agency (ex. Local Government Emergency Bridge Loan, Department of Commerce):

17. Requester Contact Information

a. First Name Last Name

b. Organization

c. E-mail Address

d. Phone Number Ext.

18. Recipient Contact Information

a. Organization

b. Municipality and County

c. Organization Type

For Profit Entity

Non Profit 501(c)(3)

Non Profit 501(c)(4)

Local Entity

University or College

Other (please specify)

d. First Name Last Name



The Florida Senate

Local Funding Initiative Request

Fiscal Year 2025-2026

LFIR # 1102

e. E-mail Address

f. Phone Number Ext.

19. Lobbyist Contact Information

a. Name

b. Firm Name

c. E-mail Address

d. Phone Number

The information provided will be posted to the Florida Senate website for public viewing if sponsored by a Senator.